Allergy to penicillin and betalactam antibiotics.
Mara Morelo Rocha FelixMarcelo Vivolo AunUllissis Pádua de MenezesGladys Reis E Silva de QueirozAdriana Teixeira RodriguesAna Carolina D'Onofrio-SilvaMaria Inês PerellóInês Cristina Camelo-NunesMaria Fernanda MalamanPublished in: Einstein (Sao Paulo, Brazil) (2021)
Betalactams are the most frequent cause of hypersensitivity reactions to drugs mediated by a specific immune mechanism. Immediate reactions occur within 1 to 6 hours after betalactam administration, and are generally IgE-mediated. They clinically translate into urticaria, angioedema and anaphylaxis. Non-immediate or delayed reactions occur after 1 hour of administration. These are the most common reactions and are usually mediated by T cells. The most frequent type is the maculopapular or morbilliform exanthematous eruption. Most individuals who report allergies to penicillin and betalactams can tolerate this group of antibiotics. To make diagnosis, a detailed medical history is essential to verify whether it was an immediate or non-immediate reaction. Thereafter, in vivo and/or in vitro tests for investigation may be performed. The challenging test is considered the gold standard method for diagnosis of betalactam hypersensitivity. The first approach when suspecting a reaction to betalactam is to discontinue exposure to the drug, and the only specific treatment is desensitization, which has very precise indications. The misdiagnosis of penicillin allergy affects the health system, since the "penicillin allergy" label is associated with increased bacterial resistance, higher rate of therapeutic failure, prolonged hospitalizations, readmissions, and increased costs. Thus, it is essential to develop strategies to assist the prescription of antibiotics in patients identified with a label of "betalactam allergy" at hospitals, and to enhance education of patients and their caregivers, as well as of non-specialist physicians.
Keyphrases
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- primary care
- palliative care
- peritoneal dialysis
- prognostic factors
- blood pressure
- emergency department
- drug induced
- patient reported outcomes
- patient reported
- angiotensin ii
- quality improvement
- adverse drug
- infectious diseases
- replacement therapy
- angiotensin converting enzyme